Comparative efficiency and hemorheological consequences of hemotransfusion and epoetin therapy in anemic cancer patients

Clinical Hemorheology and Microcirculation

Volumn 44, Issue 2, 2010, Pages 115-123

  Muravyov, A V ^a   Cheporov, S V ^b   Kislov, N V ^b   Bulaeva, S V ^a   Maimistova, A A ^a  

^a YAROSLAVL STATE PEDAGOGICAL UNIVERSITY   (Russian Federation)

^b Regional Oncological Hospital   (Russian Federation)

Author keywords

Aggregation and deformability; Anemia; Blood viscosity; Cancer; Epoetin; Hematocrit; Hemoglobin; Hemotransfusion; Red blood cells; Tyrosine kinase and phosphatase

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; BLOOD VISCOSITY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; ERYTHROCYTE AGGREGATION; ERYTHROCYTE DEFORMABILITY; ERYTHROCYTE TRANSFUSION; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HUMAN; OXYGEN TRANSPORT; PLASMA VISCOSITY; SHEAR FLOW; SOLID TUMOR;

ANEMIA; BLOOD TRANSFUSION; BLOOD VISCOSITY; ERYTHROCYTES; ERYTHROPOIETIN, RECOMBINANT; HEMOGLOBINS; HEMORHEOLOGY; HUMANS; MIDDLE AGED; NEOPLASMS; PILOT PROJECTS; PROSPECTIVE STUDIES; SIGNAL TRANSDUCTION;

EID: 77950261889     PISSN: 13860291     EISSN: None     Source Type: Journal    
DOI: 10.3233/CH-2010-1259     Document Type: Article

References (34)

1. R. Berardi, C. Braconi, G. Mantello et al., Anemia may influence the outcome of patients undergoing neo-adjuvant treatment of rectal cancer, Ann. Oncol. 12 (2006), 1221-1224.
2. N. Voravud and V. Sriuranpong, Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy, J. Med. Assoc. Thai 88 (2005), 607-612.
3. C.A. Hudis, C.L. Vogel, J.R. Gralow and D. Williams, Procrit study group. Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life, Clin. Breast Cancer 6 (2005), 132-142.
4. C. Granetto, S. Ricci, A. Martoni et al., Comparing the efficacy and safety of fixed versus weight-based dosing of epoetin alfa in anemic cancer patients receiving platinum-based chemotherapy, Oncol. Rep. 10(5) (2003), 1289-1296.
5. M.R. Nowrousian, Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours, Med. Oncol. 15 (1998), 19-28.
6. A.O. Mancuso, M. Di Molfetta, D.F. Beccaglia and E. Cortesi, A new induction schedule of epoetin alfa 40.000 IU in anemic patients with advanced lung cancer, Lung Cancer 46 (2004), 119-124.
7. J. Glaspy and Y. Beguin, Anaemia management strategies: optimizing treatment using epoetin beta (NeoRecormon), Oncology 69 (2005), 8-16.
8. D. Santini, B. Vincenzi, A. La Cesa et al., A new dose-intense epoetin alfa regimen effective in anemic cancer patients receiving chemotherapy: an open label, nonrandomized, pilot study, Anticancer Res. 25 (2005), 669-674.
9. J. Patton, M. Kuzur,W. Liggetti et al., Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy, Oncologist 9 (2004), 90-96.
10. T.J. Littlewood, J. Nortier, B. Rapoport et al., Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy, Hematol. Oncol. 21 (2003), 169-180.
11. F. Couture, A.R. Turner, B.Melosky, L. Xiu, R.K. Plante, C.Y. Lau and I. Quirt, Prior red blood cell transfusions in cancer patients increase the risk of subsequent transfusions with or without recombinant human erythropoietin management, Oncologist 10 (2005), 63-71.
12. P. Pronzato, J. Jassem and J. Mayordomo, Epoetin beta therapy in patients with solid tumours, Crit. Rev. Oncol. Hematol. 58 (2006), 46-52.
13. F. Jung, G. Pinder and H. Kiesewetter, Plasma viscosity dependence on proteins and lipoproteins: results of the Aachenstudy, Clin. Hemorheol. 12 (1992), 557-571.
14. N. Velcheva, E. Antonova, P. Titianova, N. Damianov and V. Dimitrov, Hemorheological disturbances in cerebrovascular diseases, Clin. Hemorheol. Microcirc. 39 (2008), 391-396.
15. H. Schmid-Schönbein, Blood rheology and physiology of microcirculation, Ric. Clin. Lab. 11(Suppl. 1) (1981), 13-33.
16. A. Cortinovis, A. Crippa, R. Cavalli, M. Corti and L. Cattaneo, Capillary blood viscosity in microcirculation. Clin. Hemorheol. Microcirc. 35 (2006), 183-192.
17. K. Matschke and F. Jung, Regulation of the myocardial microcirculation, Clin. Hemorheol. Microcirc. 39 (2008), 265-279.
18. M.M. Smith, P.C. Chen, C.S. Li, S. Ramanujam and A.T. Cheung, Whole blood viscosity and microvascular abnormalities in Alzheimer's Disease, Clin. Hemorheol. Microcirc. 41 (2009), 229-239.
19. F. Jung, W. Erdlenbruch, H. Koscielny and H. Kiesewetter, Influence of hyper-/isovolaemic haemodilution with hydroxyethyl starch on blood fluidity, blood flow and tissue oxygen tension in patients with POAD stage II, Clin. Hemorheol. 15 (1995), 415.
20. A.V. Muravyov, S.V. Cheporov, N.V. Kislov and E.L. Volkova, Hemorheological changes in solid tumor patients after treatment with recombinant erythropoietin, Clin. Hemorheol. Microcirc. 41 (2009), 39-47.
21. R.A. Singh, A. Sodhi, Antigen presentation by cisplatin-activated macrophages: role of soluble factor(s) and second messengers, Immunol. Cell Biol. 76 (1998), 513-519.
22. J.F. Stoltz,M. Donner, S. Muller and A. Larcan, Hemorheology in clinical practice. Introduction to the notion of hemorheologic profile, J. Mal. Vasc. 6 (1991), 261-270.
23. G.M. Artmann, Microscopic photometric quantification of stiffness and relaxation time of red blood cells in a flow chamber, Biorheology 32 (1995), 553-570.
24. A.V. Muravyov, V.V. Yakusevich, A.A. Maimistova, F.A. Chuchkanov and S.V. Bulaeva, Hemorheological efficiency of drugs, targeting on intracellular phosphodiesterase activity: in vitro study, Clin. Hemorheol. Microcirc. 24 (2007), 19-23.
25. O.K. Baskurt, M. Boynard, G.C. Cokelet, P. Connes, B.M. Cooke, S. Forconi, F. Liao, M.R. Hardeman, F. Jung, H.J. Meiselman, G. Nash, N. Nemeth, B. Neu, B. Sandhagen, S. Shin, G. Thurston and J.L.Wautier, International expert panel for standardization of hemorheological methods, Clin. Hemorheol. Microcirc. 42 (2009), 75-97.
26. P. Kenyeres, M. Rabai, A. Toth and K. Toth, New method to determine hematocrit to blood viscosity ratio and virtual optimal hematocrit, Clin. Hemorheol. Microcirc. 42 (2009), 191.
27. A. Halupa, M.L. Bailey, K. Huang et al., A novel role for STAT1 in regulating murine erythropoiesis: deletion of STAT1 results in overall reduction of erythroid progenitors and alters their distribution, Blood 15 (2005), 552-561.
28. A. Yoshimura and K. Arai, Physician education: the erythropoietin receptor and signal transduction, Oncologist 1 (1996), 337-339.
29. I. Baciu, L. Ivanof, T. Pavel et al., Erythropoietin binding to the red cell membranes, Physiologie 22 (1985), 227-231.
30. R.A. Singh, A. Sodhi, Expression and activation of lyn in macrophages treated in vitro with cisplatin: regulation by kinases, phosphatases and Ca2+/calmodulin, Biochim. Biophys. Acta 21 (1998), 171-179.
31. W. Tong, J. Zhang and H.F. Lodish, Lnk inhibits erythropoiesis and epo-dependent JAK2 activation and downstream signaling pathways, Blood 15 (2005), 4604-4612.
32. P. Boivin, Role of the phosphorylation of red blood cell membrane proteins, Biochem. J. 256 (1988), 689-695.
33. G. Minetti, A. Ciana and C. Balduini, Differential sorting of tyrosine kinases and phosphotyrosine phosphatases acting on band 3 during vesiculation of human erythrocytes, Biochem. J. 377 (2004), 489-497.
34. S. Manno, Y. Takakuwa and N. Mohandas, Modulation of erythrocyte membrane mechanical function by protein 4.1 phosphorylation, J. Biol. Chem. 280 (2005), 7581-7587.